CVS (CVS) Stock Looks Overvalued As 340B Pricing Lawsuit Looms

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

CVS Health stock has returned 74.8% over the past year, yet its broader valuation checks lean expensive, so investors are weighing a strong share price run against signals that the stock may already be pricing in a lot of good news.

Over the last 12 months, CVS Health has delivered a 74.8% return, which puts recent holders in a strong position and naturally raises the bar for what future returns need to justify today's price. Expectations around CVS Health's ability to grow healthcare and pharmacy earnings can support the current share price, while legal actions such as the Henry Ford Health lawsuit over alleged 340B drug pricing practices highlight reputational and financial risks that could affect how much investors are willing to pay. CVS Health scores 2 out of 6 on our broader valuation checks, which means the stock does not screen as a clear bargain overall even after its recent gains 2/6 valuation score.

The issue now is whether CVS Health's current valuation still leaves enough room for investors who are considering the stock after this strong run.

CVS Health delivered 74.8% returns over the last year. See how this stacks up to the rest of the Healthcare industry.

Does CVS Health Look Pricey on Earnings?

The P/E ratio is a useful way to see what investors are currently willing to pay for each dollar of CVS Health earnings. For a mature healthcare business with a mix of pharmacy, insurance and care delivery, earnings are a central anchor for valuation.

CVS Health trades on a P/E of 45.8x. That sits well above the Healthcare industry average of 25.7x and also above the peer average of 21.1x. The fair P/E multiple implied by broader factors such as sector, size and risk is 40.6x, which is still lower than where the stock currently trades, so the shares screen as overvalued on this metric. Despite the pressure from the Henry Ford Health lawsuit filed in 2024, the present multiple indicates that investors are still willing to pay a substantial premium for CVS Health earnings.

On the P/E multiple, CVS Health stock currently appears overvalued compared with both its tailored fair ratio and sector benchmarks.NYSE:CVS P/E Ratio as at Jul 2026

See what the numbers say about this price — find out in our valuation breakdown.

The CVS Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the CVS Health valuation puzzle leaves off. They explain which assumptions about CVS Health's future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price. Each narrative treats fair value as a thesis about the business that you can revisit over time rather than a single point in time. These are available on Simply Wall St's Community page.

Story Continues

Community views on CVS Health sit far apart, with one camp focused on integrated care upside and the other on complex execution risk.

Bull case: 6% undervalued

"Integration of recent and ongoing acquisitions (such as Aetna, Oak Street, and Signify Health) and vertical alignment between insurance, pharmacy, and care delivery provide substantial cross-selling and synergy opportunities..."

Read the full Bull Case to see why CVS Health could be undervalued

Bear case: roughly fairly valued

"The result has been increasing uncertainty, thanks in part to leadership changes and rising medical costs, with investors questioning whether CVS can indeed make the shift from retail to a healthcare model..."

Read the full Bear Case to see why CVS Health could be overvalued

Do you think there's more to the story for CVS Health? Head over to our Community to see what others are saying!

The Bottom Line

CVS Health currently screens as overvalued on its P/E based checks, which suggests the market is already paying a premium for its healthcare and pharmacy earnings. The broader valuation score also points to limited obvious value support if sentiment cools or if legal and execution issues become more prominent. For investors, the key question is whether CVS Health can deliver enough earnings resilience and integration progress to justify that premium, or whether the P/E multiple eventually settles closer to sector norms.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CVS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments